Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

In this week’s Pointers With Portela, the 208SkinDoc discusses the effectiveness of a minimalist anti-aging skin care routine for patients.

Researchers recently developed and validated the 3-question social comparison scale, which may be applicable outside of conditions such as eczema and psoriasis.

Addressing gender inequity in academic dermatology involves strengthening societies, celebrating female dermatologists, promoting leadership, and equitable representation, authors wrote.

The WHO underscores the significance of addressing scabies as a neglected skin disease, especially in regions with limited health care access.

A study demonstrated the favorable efficacy and safety profiles of secukinumab in patients with severe HS for up to 52 weeks.

Interim findings from the PROSPER study of mogamulizumab in adults with CTCL were recently presented orally.

The FDA has released guidelines for clinicians and tips to identify the distinguishing features of counterfeit products.

Five experts delved into the latest updates to treatment guidelines and the updated label use for dupilumab for hand-foot AD.

In recognition of Rosacea Awareness Month, Dermatology Times is reviewing research and strides in rosacea treatment over the last decade.

Test your knowledge to see if your patients would consider you an efficient texter.

Research from the GW School of Medicine and Health Sciences was recently published in the Journal of Drugs in Dermatology.

Dermatology Times is pleased to introduce one of our newest partners, Spherix Global Insights. Learn more about their vision and plans to leverage knowledge to support dermatology.

What are your rights in the instance a colleague defames you online or on social media? David Goldberg, MD, JD, shares legal advice in our April issue.

Click here to read more and answer our quiz questions in recognition of Rosacea Awareness Month.

Keep up with the latest headlines in dermatology from the past week, including UK efforts to address skin cancer disparities in skin of color, efficacy of a "virtual biopsy," and more.

ICYMI, this week we had news about Rosacea Awareness Month, topical pravibismane in diabetic foot ulcer infections, and more.

Risankizumab demonstrated the highest efficacy in PASI90 responses among analyzed IL-23 inhibitors.

Earlier this week, we shared our first Rosacea Awareness Month quiz. Review the answers and your responses below.

Treatment also shifted the expression of key biomarkers in atopic dermatitis toward non-lesional levels, according to a recent study.

To properly execute loss harvesting and reinvestment properly, without running afoul of Internal Revenue Service rules, it is crucial that one works with a professional adviser experienced in these matters.

This Rosacea Awareness Month, take a look at previous coverage from 2024.

A matching-adjusted indirect comparison found that some patients with PsA are more likely to achieve long-term treatment outcomes with bimekizumab.

In one study, researchers were unable to detect any changes in the gut microbiome of patients treated with tapering dose of steroids or a probiotic mixture.

Diagnostic accuracy of lesions was enhanced with combined dermoscopy and reflectance confocal microscopy, according to one study.